KC-4950

K562-BCMA-GFP-Luc2 Cell Line

×
59800
Home » K562-BCMA-GFP-Luc2 Cell Line

Background of K562-BCMA-GFP-Luc2 Cell Line

TNFRSF17 encodes TNF receptor superfamily member 17 and is also known as BCM. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation.

Specifications

Catalog NumberKC-4950
Cell Line NameK562-BCMA-GFP-Luc2 Cell Line
NCBI/UniProt Accession NumberNM_001192.2
Clone Number8-9#
Host Cell LineK562-Luc2-GFP
DescriptionK562-BCMA-GFP-Luc2 is a stable engineered cell line expressing human BCMA-GFP-Luc2
QuantityOne vial of frozen cells (≥2×10⁶ cells/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640+20% FBS+10% DMSO
Propagation MediumRPMI1640+10%FBS+1μg/mL Puromycin
Selection MarkerPuromycin
MorphologyLymphoblast
SubcultureSplit at a ratio of 1:4–1:6 every 2–3 days
Incubation37 °C with 5% CO₂
StorageLiquid nitrogen immediately upon receiving
Doubling TimeEstimated 19–36 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

K562-BCMA-GFP-Luc2 cell line was generated using a lentiviral vector expressing the human BCMA-GFP-Luc2 sequence.

Characterization

Figure 1: Characterization of human BCMA overexpression in the K562-BCMA-GFP-Luc2 stable clone using FACS.

Figure 2: Characterization of human BCMA overexpression in the K562-BCMA-GFP-Luc2 stable clone using PCR sequence.

Figure 3: Characterization of human GFP overexpression in the K562-BCMA-GFP-Luc2 stable clone using FACS.

Figure 4: K562 cells expressing BCMA mutant were seeded into 96-well plates, treated with compounds for 72 hours, and then read out with Cell-Titer Glo system.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO₂ incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4–1:6 every 2–3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

  1. Ji J, Zhao X, Wang B et al. Efficacy and specific toxicity profiles of GPRC5D- versus BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: a meta-analysis of clinical trials and real-world studies. Frontiers in immunology. 2026;17:1937154. PMID: 42871283. doi: 10.3389/fimmu.2026.1937154.
  2. Martino M, Bilardi E, Pitea M et al. BCMA-Targeted Immunotherapy in Early Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Practical Management. European journal of haematology. 2026 Oct 7;:. PMID: 42841179. doi: 10.1111/ejh.70328.
  3. Al-Momany HT, Kaylani DZ, Abuhashem O et al. Salvage outcomes with teclistamab after BCMA-directed therapy failure in relapsed/refractory multiple myeloma: a systematic review and meta-analysis. Current problems in cancer. 2026 Sep 18;65:101343. PMID: 42759103. doi: 10.1016/j.currproblcancer.2026.101343.

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.